Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE

Abstract Objectives To investigate whether abnormal BMI is associated with adverse health-related quality of life (HRQoL) outcome, including severe fatigue, after 52 weeks of standard therapy plus belimumab or placebo in patients with SLE. Methods We analysed data from the BLISS-52 (NCT00424476) and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2021-09, Vol.60 (9), p.4205-4217
Hauptverfasser: Borg, Alexander, Gomez, Alvaro, Cederlund, Arvid, Cobar, Flordelyn, Qiu, Victor, Lindblom, Julius, Emamikia, Sharzad, Enman, Yvonne, Pettersson, Susanne, Parodis, Ioannis
Format: Artikel
Sprache:eng
Schlagworte:
Clinical Science
Medicin och hälsovetenskap
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Objectives To investigate whether abnormal BMI is associated with adverse health-related quality of life (HRQoL) outcome, including severe fatigue, after 52 weeks of standard therapy plus belimumab or placebo in patients with SLE. Methods We analysed data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (n = 1684). Adverse HRQoL was defined as SF-36 scores ≤ the fifth percentile in age- and sex-matched US population-based subjects, and FACIT-F scores
ISSN:1462-0324
1462-0332
1462-0332
DOI:10.1093/rheumatology/keaa909